Drug Trial Radar · NCT06118255
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
May 21, 2024
Primary completion
Sep 1, 2026
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- UCB BIOSCIENCES, Inc.UCB
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 23 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.
Conditions
- Dravet Syndrome
Interventions
fenfluramineDrug
The study drug, fenfluramine HCl, is an oral solution to be administered in equal doses twice daily (BID). It will be based on the current dose and participant's weight (kg).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in QT interval corrected by Fridericia (QTcF) at Visit 13 (End of Treatment/Early Termination (EOT/ET))Time frame: Week 52 (Visit 13; EOT/ET), compared to Baseline
- Occurrence of a treatment-emergent (ie, post-Baseline through Visit 13 [EOT/ET]) result which meets the FDA case definition of drug associated valvulopathyTime frame: From post-Baseline (Day 1) through Visit 13 (EOT/ET) (up to 52 weeks)
- Occurrence of treatment-emergent (ie, post-Baseline through Visit 13 [EOT/ET]) clinically confirmed valvular heart disease (VHD)Time frame: From post-Baseline (Day 1) through Visit 13 (EOT/ET) (up to 52 weeks)
- Change from Baseline in body weight (Z-score) at each visitTime frame: Week 1 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 7), Week 12 (Visit 8), Week 16 (Visit 9), Week 20 (Visit 10), Week 26 (Visit 11), Week 39 (Visit 12), Week 52 (Visit 13), Postdose Safety Follow-Up (Visit 14), compared to Baseline
- Change from Baseline in recumbent length (Z-score) at each visitTime frame: Week 1 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 7), Week 12 (Visit 8), Week 16 (Visit 9), Week 20 (Visit 10), Week 26 (Visit 11), Week 39 (Visit 12), Week 52 (Visit 13), Postdose Safety Follow-Up (Visit 14), compared to Baseline
- Occurrence of a clinically significant abnormality on the neurological examination at each visitTime frame: Week 1 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 7), Week 12 (Visit 8), Week 16 (Visit 9), Week 20 (Visit 10), Week 26 (Visit 11), Week 39 (Visit 12), Week 52 (Visit 13), Postdose Safety Follow-Up (Visit 14), compared to Baseline
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
Ep0213 105
Memphis, Tennessee
Ep0213 107
Dallas, Texas
Ep0213 103
Seattle, Washington
Ep0213 502
Brussels, Belgium
Ep0213 501
Edegem, Belgium
Ep0213 303
Bielefeld, Germany
Ep0213 202
Florence, Italy
Ep0213 203
Genova, Italy
Ep0213 201
Roma, Italy
Ep0213 204
Roma, Italy
Ep0213 403
Glasgow, United Kingdom
Ep0213 401
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.